Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89.6M
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
63.8M
-
Shares change
-
+1.88M
-
Total reported value, excl. options
-
$846M
-
Value change
-
+$19.5M
-
Put/Call ratio
-
0.69
-
Number of buys
-
80
-
Number of sells
-
-35
-
Price
-
$13.26
Significant Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q3 2023
156 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2023.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.8M shares
of 89.6M outstanding shares and own 71.19% of the company stock.
Largest 10 shareholders include Alphabet Inc. (10.5M shares), FMR LLC (6.58M shares), ARK Investment Management LLC (5.2M shares), VANGUARD GROUP INC (4.83M shares), BlackRock Inc. (4M shares), STATE STREET CORP (3.28M shares), Casdin Capital, LLC (2.95M shares), FEDERATED HERMES, INC. (2.53M shares), JPMORGAN CHASE & CO (2.51M shares), and Nikko Asset Management Americas, Inc. (2.15M shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.